A Phase 1a Study of IMR-687 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs IMR 687 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man
- Sponsors Imara Inc
- 17 Oct 2017 Status changed from recruiting to completed, according to Cydan media release.
- 14 Sep 2017 According to Imara Inc media release, new data will be presented at the 6th Annual Sickle Cell Therapeutics Conference.
- 15 May 2017 According to Imara Inc media release, company anticipates results from this study in the summer of 2017.